Clinical trial · Interventional
Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone
Zhongshan Hospital, Fudan University
NCT03988686CI-TRIAL-00039090unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to examine whether radical prostatectomy can impact survival and quality-of-life in men with oligo-metastatic prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radical prostatectomy plus standard care | Procedure | — | UNRESOLVED |
| Standard of care for metastatic prostate cancer | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention Group
- description
- Radical prostatectomy plus standard care
- interventionNames
- Procedure: Radical prostatectomy plus standard care
- Drug: Standard of care for metastatic prostate cancer
- type
- ACTIVE_COMPARATOR
- label
- Comparator Group
- description
- Standard care, currently ADT +/- other systemic therapies.
- interventionNames
- Drug: Standard of care for metastatic prostate cancer
Primary outcomes (1)
- measure
- the time to castrate resistance
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Participants is willing and able to give informed consent for participation in the study * Male aged 19-75 years. * Diagnosed with oligo-metastatic prostate cancer (1-3 skeletal lesions on bone specific imaging, no visceral metastases). * Locally resectable tumor (clinical/radiological stage T1-T3). * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Suitable for radical prostatectomy within 12 months of starting standard care. Exclusion Criteria: * Contraindications to radical prostatectomy. * Visceral metastases. * Prior radiotherapy to the abdomen/pelvis or to skeletal metastases. * Any systemic therapy of prostate cancer (including standard care) for 12 or more months prior to enrollment. * Current involvement in other interventional research.
References
Publications (0)
Data not yet available
No reference posted for this study.